ALKS-8700

• CAT Number: I006496
• CAS Number: 1577222-14-0
• Molecular Formula: C11H13NO6
• Molecular Weight: 255.226
• Purity: ≥95%
• Synonyms: Diroximel fumarate; ALKS8700; ALKS 8700; ALKS-8700;2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl fumarate
• Target: Keap1-Nrf2
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: 4-O-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 1-O-methyl (E)-but-2-enedioate
• InChI: InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+
• InChIKey: YIMYDTCOUQIDMT-SNAWJCMRSA-N
• SMILES: COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O

ALKS-8700(CAT: I006496) is an investigational drug that is being developed by Alkermes as a potential treatment for multiple sclerosis (MS). It is an oral prodrug of monomethyl fumarate (MMF), which is the active metabolite of dimethyl fumarate (DMF), a drug that is currently approved for the treatment of MS. ALKS-8700 is designed to offer a more convenient dosing regimen and potentially lower gastrointestinal side effects compared to DMF. It works by activating the nuclear factor erythroid-derived 2-like 2 (Nrf2) pathway, which leads to the upregulation of antioxidant and anti-inflammatory genes, ultimately reducing the neuroinflammation that is associated with MS. ALKS-8700 has completed several clinical trials, and the results have been promising.